INOVIQ LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.53 AUD | +7.07% |
|
+7.07% | -20.30% |
| Apr. 19 | INOVIQ Concludes Analytical Validation for Ovarian Cancer Blood Test | MT |
| Apr. 15 | Fears of Middle East Conflict Escalation Quell Appetite for Australian Shares | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 900K 594K | Sales 2025 * | 1.6M 1.06M | Capitalization | 48.77M 32.19M |
|---|---|---|---|---|---|
| Net income 2024 * | -9M -5.94M | Net income 2025 * | -8M -5.28M | EV / Sales 2024 * | 46.3 x |
| Net cash position 2024 * | 7.1M 4.69M | Net Debt 2025 * | 8.9M 5.87M | EV / Sales 2025 * | 36 x |
| P/E ratio 2024 * |
-5.41
x | P/E ratio 2025 * |
-7.07
x | Employees | 15 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 71.68% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +7.07% | ||
| 1 week | +7.07% | ||
| Current month | +6.00% | ||
| 1 month | -5.36% | ||
| 3 months | +4.95% | ||
| 6 months | -11.67% | ||
| Current year | -20.30% |
1 week
0.48
0.53
1 month
0.480.72
Current year
0.480.92
1 year
0.470.99
3 years
0.392.69
5 years
0.395.60
10 years
0.185.60
| Managers | Title | Age | Since |
|---|---|---|---|
Leearne Hinch
CEO | Chief Executive Officer | - | 16-11-06 |
Mark Edwards
DFI | Director of Finance/CFO | - | 22-11-01 |
Gregory Rice
CTO | Chief Tech/Sci/R&D Officer | - | 21-09-19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | Nov. 28 | |
Philip Powell
BRD | Director/Board Member | 65 | 19-06-17 |
Geoff Cumming
BRD | Director/Board Member | - | 20-07-27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 0.53 | +7.07% | 47,065 |
| 24-05-09 | 0.495 | +2.06% | 66,843 |
| 24-05-08 | 0.485 | 0.00% | 22,708 |
| 24-05-07 | 0.485 | -3.00% | 6,133 |
| 24-05-06 | 0.5 | +1.01% | 48,403 |
Delayed Quote Australian S.E., May 10, 2024 at 02:10 am EDT
More quotes
INOVIQ Ltd is an Australia-based company. The Company is engaged in developing and commercializing exosome solutions and precision diagnostics to improve the diagnosis and treatment of cancer and other diseases. It operates in one segment, the research and development of cancer diagnostics. The Company has two products in market, which include hTERT ICC test and the EXO-NET Pan-Exosome. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate and other cancers. The hTERT test is an immunocytochemistry (ICC) assay registered for the detection of human telomerase reverse transcriptase (hTERT) in cytopathology samples. It is used as an adjunct to urine cytology to help resolve indeterminate cytology results and identify patients with increased risk of bladder cancer. EXO-NET is a research use only (RUO) pan-exosome capture tool for the isolation of exosomes from body fluids including plasma, urine and saliva.
Calendar
2024-08-26
- Q4 2024 Earnings Release (Projected)
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.30% | 32.2M | |
| +17.96% | 44.96B | |
| +48.77% | 41.85B | |
| +1.17% | 42.65B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- IIQ Stock